Healthcare Industry News:  CardiacAssist 

Devices Interventional Cardiology

 News Release - October 7, 2014

CardiacAssist Announces the First Human Use of Its PROTEK DUO(TM) Veno-Venous ECLS Kit

Texas man is the world’s first to receive the PROTEK Duo for treatment following surgery

PITTSBURGH--(Healthcare Sales & Marketing Network)--CardiacAssist, Inc. today announced that the first PROTEK Duo veno-venous extracorporeal life support (VV ECLS) kit was utilized on Wednesday, September 24th, at Memorial Hermann Hospital in Houston, Texas. According to statements from the world-renowned heart failure team led by Dr. Biswajit Kar, Dr. Pranav Loyalka and Dr. Igor Gregoric, the PROTEK Duo ECLS kit was utilized when one patient’s heart function continued to deteriorate despite the successful implantation of a long-term left ventricular assist device (LVAD).

The PROTEK Duo cannula was placed during a short, minimally-invasive percutaneous procedure in the cardiac catheterization lab before returning the patient to the hospital’s cardiac intensive care unit, where many of the pharmaceuticals upon which the patient was dependent were able to be weaned. In combination with the TandemHeart® pump, the PROTEK Duo was reported to deliver 4.0 Liters per minute of blood flow, allowing the patient’s native heart to rest while augmenting flow to the implantable LVAD. The patient is now in the process of being weaned from the device and the outlook is favorable despite a long road to full recovery.

“Our team prides itself on our ability to offer patients the most advanced treatment options and technologies. On behalf of the entire team, I’d like to say that we are very proud to be the first center to use the PROTEK Duo as this technology provides a new opportunity to support a group of patients that previously had few alternatives,” said Dr. Biswajit Kar, Chief of the Medical Division Center for Advanced Heart Failure and Professor of Internal Medicine at Memorial Hermann Hospital. “The PROTEK Duo performed well and we plan on making it a permanent part of our treatment arsenal.”

The PROTEK Duo veno-venous cannula recently received FDA 510(k) clearance as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during ECLS procedures. Upon clearance, CardiacAssist initiated a limited commercial release in September and expects to begin full commercial release before the end of the year. “I would like to congratulate our team for bringing this revolutionary product through development and into commercial launch in record time,” said John Marous, President and CEO of CardiacAssist. “We are extremely happy with PROTEK Duo’s performance in the first of many opportunities to help patients in need.”

About CardiacAssist

CardiacAssist is a growing, privately-held medical technology company headquartered in Pittsburgh, Pennsylvania, that developed the world’s first FDA-cleared and CE-marked short-term extracorporeal circulatory support platform designed for both interventional cardiologists and cardiac surgeons. The TandemHeart system has provided critical heart support to thousands of patients in the top cardiac centers worldwide. Its unique left atrial cannulation approach enables fully percutaneous bypass of the left ventricle and augments the native pumping capability of the heart by more than 80%.


Source: CardiacAssist

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.